Arch Pharm Res 27(1):3134 Giroux EL et al (1972) Competition for zinc among serum albumin and amino acids
April 29 Product: X4 Pharmaceuticals Xolremdi Indication: WHIM Syndrome The FDA approved X4 Pharmaceuticals Xolremdi Monday as the first targeted treatment for WHIM syndrome, an ultra-rare immunodeficiency disease named for its four characteristics: warts, hypogammaglobulinemia, infections and myelokathexis
Patch clamp electrophysiology studies showed significantly increased synapse density in hippocampal tissue
For the subjective measure scores (CADSS and PSI), as these were only measured at one time point for each condition, only condition was included as a fixed effect
Clin Chem Lab Med (1999) 37:2816.10.1515/CCLM.1999.049 15 BaynesRDBezwodaWR
Daily use, high concentrations, or stacking multiple copper products